Dupont Capital Management Corp purchased a new stake in Calithera Biosciences, Inc. (NASDAQ:CALA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,394 shares of the biotechnology company’s stock, valued at approximately $258,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in CALA. Legal & General Group Plc bought a new position in Calithera Biosciences in the second quarter valued at approximately $120,000. KCG Holdings Inc. acquired a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $144,000. Paloma Partners Management Co acquired a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $160,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Calithera Biosciences in the second quarter valued at approximately $166,000. Finally, GAM Holding AG acquired a new stake in shares of Calithera Biosciences in the second quarter valued at approximately $206,000. 71.88% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/14/dupont-capital-management-corp-invests-258000-in-calithera-biosciences-inc-cala-stock.html.

CALA has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Monday, November 6th. BidaskClub downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, William Blair initiated coverage on shares of Calithera Biosciences in a report on Thursday, October 5th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $15.17.

Shares of Calithera Biosciences, Inc. (NASDAQ CALA) opened at $11.72 on Tuesday. Calithera Biosciences, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.02 million. analysts forecast that Calithera Biosciences, Inc. will post -0.77 earnings per share for the current fiscal year.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 16.30% of the stock is currently owned by insiders.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences, Inc. (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.